NCT05563844View on ClinicalTrials.gov

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 1, 2026

Conditions
Diffuse Large B Cell Lymphoma，DLBCL
Interventions
DRUG

PM 8.4 mg/m^2

The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.

DRUG

PM 11.2 mg/m^2

The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.

Trial Locations (2)

200025

Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai

610000

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Chengdu Zenitar Biomedical Technology Co., Ltd

INDUSTRY